Metastatic Prostate Cancer Clinical Trials

52 recruiting

Metastatic Prostate Cancer Trials at a Glance

66 actively recruiting trials for metastatic prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 2 with 22 trials, with the heaviest enrollment activity in New York, Madrid, and Baltimore. Lead sponsors running metastatic prostate cancer studies include Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Novartis Pharmaceuticals, and The First Affiliated Hospital with Nanjing Medical University.

Browse metastatic prostate cancer trials by phase

Treatments under study

About Metastatic Prostate Cancer Clinical Trials

Looking for clinical trials for Metastatic Prostate Cancer? There are currently 52 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 66 trials

Recruiting
Phase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled142 locationsNCT05939414
Recruiting
Phase 1

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer (mCRPC)
Novartis Pharmaceuticals15 enrolled4 locationsNCT07174063
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.210 enrolled25 locationsNCT05800665
Recruiting
Phase 3

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Canadian Cancer Trials Group236 enrolled14 locationsNCT06439225
Recruiting
Phase 2

A Study of Tarlatamab for People With Prostate Cancer

Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center32 enrolled10 locationsNCT07111507
Recruiting
Phase 1Phase 2

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Metastatic Prostate Cancer
AstraZeneca177 enrolled51 locationsNCT07181161
Recruiting
Phase 2Phase 3

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Prostate CancerMetastatic Prostate CancerOligometastasis+3 more
VA Office of Research and Development464 enrolled20 locationsNCT04787744
Recruiting
Phase 2

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Castration Resistant Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins150 enrolled6 locationsNCT04363164
Recruiting

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Metastatic Prostate Cancer
Novartis Pharmaceuticals170 enrolled1 locationNCT07290270
Recruiting

Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration

Metastatic Prostate Cancer (mPC)
European Institute of Oncology125 enrolled1 locationNCT06762379
Recruiting
Phase 1

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Prostate CancerMetastatic Prostate Cancer
University of California, San Francisco30 enrolled1 locationNCT07145177
Recruiting
Phase 2

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

Prostate CancerMetastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute26 enrolled2 locationsNCT05751941
Recruiting
Phase 1

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Prostate Cancer PatientsRecurrent Prostate CancerOligometastatic Prostate Cancer (OMPC)+1 more
University of Wisconsin, Madison14 enrolled1 locationNCT07090148
Recruiting
Phase 1Phase 2

Study of AZD0754 in Participants With Metastatic Prostate Cancer

Metastatic Prostate Cancer
AstraZeneca60 enrolled15 locationsNCT06267729
Recruiting
Phase 2

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins58 enrolled1 locationNCT06616597
Recruiting
Phase 4

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Metastatic Breast CancerMetastatic Prostate Cancer
Ottawa Hospital Research Institute50 enrolled3 locationsNCT07252726
Recruiting
Not Applicable

Physician- and Patient-based Barriers to NGS Testing

Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins256 enrolled1 locationNCT07209176
Recruiting

Pharmaceutical Management in Targeted Radioligand Therapy

CancerThyroid CancerMetastatic Prostate Cancer+1 more
Hospices Civils de Lyon600 enrolled3 locationsNCT07389512
Recruiting
Not Applicable

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

Oligometastatic Prostate Cancer
British Columbia Cancer Agency168 enrolled4 locationsNCT04610372
Recruiting
Phase 2

Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer

Metastatic Prostate Cancer
Sun Yat-sen University104 enrolled1 locationNCT06854250